{"entity":{"id":"jnj-90014496","kind":"drug","name":"JNJ-90014496","aka":[],"tldr":"JNJ-90014496 is an experimental CAR-T cell therapy from Janssen Research & Development in phase 2 trials for hodgkin lymphoma and diffuse large B-cell lymphoma, aimed at CD19 and CD20.","summary":"JNJ-90014496 is a CAR-T cell therapy developed by Janssen Research & Development. Its targets are CD19 and CD20 (the sponsor names CD20 x CD19). The sponsor states: An autologous dual-targeting chimeric antigen receptor (CAR) T-cell therapy directed against both CD20 and CD19, enabling the engineered T cells to attack lymphoma cells expressing either or both antigens. ClinicalTrials.gov describes the intervention as: JNJ-90014496, an autologous dual targeting chimeric antigen receptor (CAR) - T cell therapy targeting Cluster of differentiation (CD)20 and CD19. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in hodgkin lymphoma and diffuse large B-cell lymphoma. The largest, NCT05421663, plans to enrol 166 participants (actual) with primary completion expected 2041-07-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of JNJ-90014496","url":"https://clinicaltrials.gov/search?intr=JNJ-90014496"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hodgkin-lymphoma","dlbcl"],"sections":[],"technologies":[],"targets":["cd19","cd20"],"drugs":[],"companies":["johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05421663"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"CAR-T cell therapy","mechanism":"An autologous dual-targeting chimeric antigen receptor (CAR) T-cell therapy directed against both CD20 and CD19, enabling the engineered T cells to attack lymphoma cells expressing either or both antigens.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/jnj-90014496/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"},{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"}],"company":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"}],"trial":[{"id":"nct05421663","kind":"trial","name":"A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma","route":"/trials/nct05421663/"}]}}